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the	 electronic	 version	 that	 has	 the	 greater	 number	 of	 benefits	 for	 patients.	 The	main	 benefit	 of	 the	


















Patient	 Information	Leaflets	 (PILs)	are	commonly	referred	to	by	a	number	of	terms	 including;	







be	written	 in	 accordance	with	 the summary	of	product	 characteristics	 (SmPC)	 and	has	 to	be	
aligned	with	Article	59	of	Directive	2001/83/EC.	The	SmPC	is	required	to	provide	professionals	
prescribing	medication	 a	 ‘neutral,	 objective	 source	of	 information	 about	products’	 (Van	Dijk,	
2014).	The	key	point	of	the	SmPC	is	that	it	is	information	for	professional	use	not	patient	use,	





most	 current	 information.	 At	 present,	 patients	 may	 not	 always	 have	 the	 most	 current	 PIL	
version	 in	 their	 medicine	 carton.	 New	 variations	 to	 PILs	 are	 regularly	 approved	 by	 health	
authorities,	 this	 PIL	 version	 then	 becomes	 the	 effective	 version	 and	 is	 distributed	 with	









and	 avoiding	 the	 use	 technical	 jargon.	 The	 use	 of	 plain	 English	 is	 particularly	 important	 in	
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the	use	of	plain	English	 is	Health	Canada.	 In	 their	 guidance	 they	 suggest	using	 ‘the	 simplest,	
most	 common	words	 possible’,	 the	 reason	 being	 that	 it	 ensures	 that	 the	 information	 being	
provided	is	‘clear,	concise	and	easy	to	understand	for	the	intended	audience’	(Health	Canada,	
2014a).	 It	 is	 specified	 in	 Health	 Canada’s	 guidance	 that	 the	 vocabulary	 used	 in	 PILs	 is	
appropriate	 for	 ‘Grades	 6-8	 reading	 level’	 (Health	 Canada,	 2014b),	 this	 equates	 to	
approximately	an	11-14	yearold	age	group.	
	
When	 it	 comes	 to	 reading	 PILs,	 people	 are	 highly	 selective.	 In	 the	 September	 2020	 issue	 of	
Regulatory	Rapporteur,	Dr.	 Theo	Raynor	 is	 a	professor	at	 Leeds	University,	who	has	 critically	
researched	the	impact	of	European	legislation	on	medicine	leaflets,	he	is	considered	a	leading	
figure	 in	 the	 European	 consumer	 medicines	 information	 movement	 and	 views	 having	 an	
informed	patient	as	being	a	goal	in	itself.	(School	of	Pharmacy	University	Wisconsin,	2013).	Dr.	
Raynor	has	been	involved	in	many	studies	and	articles	on	PILs.	In	a	September	2020	interview	
published	 in	Regulatory	Rapporteur	he	stated	 that	 ‘people	 tend	not	 to	value	pieces	of	paper	
that	fall	out	of	boxes’	(Stewart,	2020).	David	Sless	of	the	Communication	Research	Institute	lists	
some	common	characteristics	of	a	PIL	reader	in	his	book	‘Writing	about	Medicines	for	People:	















Other	 studies	 have	 been	 performed	 to	 assess	 patients’	 attitudes	 to	 the	 PIL.	One	 particularly	










common	 issue	 selected	 by	 survey	 participants	 was	 that	 package	 inserts	 are	 difficult	 to	




believes	 that	 the	 electronic	 provisions	 for	 package	 insert	 information	 will	 change	 people’s	
attitudes	to	PILs	(Stewart,	2020).	
	
In	 January	 2020,	 the	 European	Medicines	Agency	 (EMA),	 along	with	 the	Heads	of	Medicines	
Agencies	 (HMA)	 and	 the	 European	 Commission	 (EC)	 published	 a	 report	 called	 ‘Electronic	
product	information	for	human	medicines	in	the	EU:	key	principles’	(EMA-HMA-EC,	2020).	The	
collaboration	report	states	that	‘developing	an	electronic	format	is	the	most	pressing	priority	of	
the	 actions	 from	 public-health	 perspective’,	 the	 reason	 being	 is	 that	 ‘it	 will	 facilitate	 timely	
access	to	up-to-date	information’	(EMA-HMA-EC,	2020). The	report	calls	for	the	introduction	of	
an	electronic	product	information	(ePI)	be	introduced.	This	ePI	will	see	patient	information	that	





The	 ePI	 will	 not	 be	 a	 replacement	 for	 the	 current	 format	 and	 it	 ‘is	 intended	 to	 expand	 the	
formats’	rather	than	‘remove	or	substitute’,	the	reason	they	state	for	this	is	that	the	‘paper	PL	





‘that	 app	developers	will	 be	able	 to	 incorporate	 information	 from	package	 leaflets	 into	 their	
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Interviews	 with	 regulatory/industry	 experts	 were	 included	 in	 this	 assessment	 to	 determine	
these	 expert’s	 opinions	 on	 the	 ePIL	 versus	 the	 paper	 PIL,	 and	 which	 is	 the	 more	 effective	




As	Australia	already	utilise	an	electronic	PIL,	or	Consumer	Medicine	 Information	(CMI)	as	 it	 is	
named,	 the	 first	 expert	was	 able	 to	 offer	 insight	 on	 its	 use	 in	 Australia.	 The	 negative	 of	 the	













patients,	 in	 that	 patients	 are	 sometimes	 dispensed	medications	 without	 the	 PIL.	 This	 arises	
when	 the	 pharmaceutical	 company,	 complying	 with	 the	 legislation	 supplies	 a	 PIL	 with	 the	









called	 split	or	broken	packs	where	 the	blister	may	contain	 ten	 tablets	but	 if	 a	prescription	 is	
only	 for	 seven	 tablets,	 the	 pharmacy	 will	 cut	 the	 blister	 to	 the	 prescribed	 quantity	 blister,	
meaning	it	may	not	get	delivered	in	its	original	box	and	thus	the	PIL	is	not	supplied.	This	issue	is	
an	area	where	there	was	extraordinarily	little	information	available	to	assess	its	impact,	as	part	






Interviews	were	 also	 carried	 out	with	 a	 number	 of	 community	 pharmacists	 as	 they	 are	well	
positioned	to	understand	the	common	queries	patients	have	with	the	PIL	in	its	current	format.	
Two	 of	 the	 pharmacists	 were	 based	 in	 Ireland	 while	 one	 was	 based	 in	 London.	 All	 three	
pharmacists	 were	 aware	 of	 the	 practices	 of	 dispensing	 medicines	 from	 bulk	 supplies	 and	
splitting	 or	 breaking	 blister	 packs,	 the	 difference	 however	 was	 that	 the	 London	 based	
pharmacist	always	printed	and	issued	a	PIL,	as	was	the	policy	of	the	pharmacy	where	she	was	
employed,	 while	 the	 pharmacists	 working	 in	 Ireland	 did	 not	 typically	 supply	 a	 PIL	 when	
dispensing	medicines	without	 their	 original	 packaging.	 Both	 the	 Irish	 based	 pharmacists	 said	
that	 it	would	be	a	 very	 rare	occurrence	 that	a	patient	would	 come	back	 to	 the	pharmacy	 to	






















+60	 age	 categories	 paper	 copies	 of	 the	 survey	 were	 distributed	 to	 a	 local	 ballroom	 dance	
studio,	 that	 has	 several	 members	 in	 this	 age	 category	 and	 a	 retiree’s	 association	 was	 also	
contacted.	Lindemann’s	2019	benchmark	study	on	survey	responses	states	that	a	‘survey	with	
more	than	12	questions	or	takes	longer	than	5	minutes	to	complete	see	a	15%	drop	in	response	
rate’	 (Lindemann,	2019)	–	 for	 this	 reason	 twelve	 (12)	questions	were	 set	 and	SurveyMonkey	


























first	 time.	With	26%	Selecting	 ‘Always’	 for	reading	the	PIL	of	a	 frequently	used	medication	 in	























In	an	attempt	 to	 identify	 the	main	 issues	people,	have	with	 the	PIL	 they	were	asked	 to	 rank	
from	 ‘Disagree	 Completely’	 to	 ‘Completely	 Agree’	 for	 the	 usefulness	 of	 the	 PIL,	 the	 ease	 of	
understanding	the	PIL	and	the	ability	to	fold	and	return	it	to	its	box.	The	results	to	this	question	
demonstrated	 that	 for	 Usefulness	 of	 the	 PIL	 and	 it	 being	 easy	 to	 read	 understood	 –	 the	
majority	of	people	 selected	 ‘Agree	Somewhat’,	with	 this	option	being	 selected	47%	and	41%	














Survey	 volunteers	were	 asked	 how	 they	would	 like	 to	 receive	 the	 PIL	 in	 the	 future. 45%	 of	
respondents	 selected	 ‘As	 it	 is	 now,	 paper	 form’,	 27%	 selected	 ‘Electronically’,	 24%	 selected	
‘Printed	at	Pharmacy’	and	4%	selected	 ‘Other.	 In	order	 for	 the	pharmacist	 to	print	 the	PIL,	 it	
would	 need	 to	 be	 online,	 therefore	 a	move	 to	 ePILs	would	 be	 required	 to	 facilitate	 51%	 of	
10


























As	 it	 is	 now,	 in	 paper	
form	









‘Could	 be	 kept	 separately	 to	 the	 medicine/no	 need	 to	 try	 fit	 back	 into	 the	
package/box’.	








































The	 legislation	surrounding	PILs	 in	Europe	was	assessed	against	 the	regulations	and	guidance	














In	 the	 1990’s,	 the	 regulations	 in	 Australia	 were	 updated	 so	 that	 it	 was	 no	 longer	 a	 legal	
requirement	for	the	CMI	to	be	supplied	for	Schedule	2	medicines,	but	it	was	a	requirement	for	
it	 to	 be	 included	 for	 Schedule	 3	 and	 Schedule	 4	medicines.	 The	 CMI	 can	 be	made	 available	
online,	printed	in	the	pharmacy	or	sometimes	distributed	with	the	carton,	however	if	a	PIL	is	to	
be	provided	in	this	format	it	becomes	part	of	the	labelling	and	packaging	and	is	subject	to	other	
regulatory	 guidance.	 To	 ensure	 the	 patient	 has	 direct	 access	 to	 the	 correct	 PIL,	 medicine	
cartons	in	Australia	often	include	a	QR	code,	which	can	be	scanned	by	the	user.	

























Many	 studies	 and	 articles	 have	 indicated	 that	 the	 current	 format	 of	 PILs	 ‘does	 not	 meet	
patient’s	 needs’	 (Blanck,	 2012).	 The	 negatives	 and	 the	 positives	 of	 both	 the	 paper	 and	 the	
electronic	formats	of	the	PIL	were	assessed	from	the	literature	review,	the	interviews,	and	the	
survey	 to	determine	which	of	 the	 two	formats	would	be	more	beneficial	 to	patients.	Table	5	
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Many	 of	 the	 survey	 participants	 stated	 that	 they	 felt	 the	 ePIL	 was	 a	 more	 environmentally	
friendly	option	 in	comparison	to	the	paper	 format.	The	survey	results	demonstrated	that	 the	




(Stewart,	 2020),	 a	 further	 advantage	 according	 to	Dr.	 Raynor	 is	 ‘that	 app	 developers	will	 be	
able	to	 incorporate	information	from	package	leaflets	 into	their	applications’	(Stewart,	2020).	
By	it	being	online	it	ensures	that	the	most	current	version	of	the	PIL	is	available	to	patients	–	
however	given	 that	 it	 is	unclear	 if	patients	are	even	aware	 that	 they	may	not	be	getting	 the	
most	 current	 version	 of	 a	 PIL	 with	 their	medicines,	 it	 has	 yet	 to	 be	 determined	 if	 they	 will	
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